Preemptive therapy in the 2 randomization arms
| Parameter . | Whole patient population . | P . | |
|---|---|---|---|
| DNAemia arm . | Antigenemia arm . | ||
| No. of patients | 89 | 89 | na |
| No. (%) of HCMV infected patients | 30 (34) | 37 (42) | ns |
| No. (%) of treated patients | 16 (18) | 28 (31) | .037 |
| Median days (range) to start of antiviral therapy | 56 (17-144) | 45 (22-88) | .032 |
| Median days (range) of first course of antiviral therapy | 15 (6-35) | 14 (5-39) | ns |
| No. (%) of relapsing HCMV infections | 8/16 (50) | 15/28 (54) | ns |
| No. (%) of treated relapses | 3/16 (19) | 10/28 (36) | ns |
| Median days (range) of relapse treatment | 11 (7-52) | 14 (7-49) | ns |
| Median days (range) of total antiviral therapy | 17 (6-69) | 17 (5-69) | ns |
| Median days (range) of total antiviral therapy: | |||
| in patients with grade 0-I acute GvHD | 12 (6-20) | 14 (7-66) | ns |
| in patients with grade II-IV acute GvHD | 20 (6-69) | 23 (5-69) | ns |
| P grade 0-I vs grade II-IV | (0.08) | (ns) | na |
| Parameter . | Whole patient population . | P . | |
|---|---|---|---|
| DNAemia arm . | Antigenemia arm . | ||
| No. of patients | 89 | 89 | na |
| No. (%) of HCMV infected patients | 30 (34) | 37 (42) | ns |
| No. (%) of treated patients | 16 (18) | 28 (31) | .037 |
| Median days (range) to start of antiviral therapy | 56 (17-144) | 45 (22-88) | .032 |
| Median days (range) of first course of antiviral therapy | 15 (6-35) | 14 (5-39) | ns |
| No. (%) of relapsing HCMV infections | 8/16 (50) | 15/28 (54) | ns |
| No. (%) of treated relapses | 3/16 (19) | 10/28 (36) | ns |
| Median days (range) of relapse treatment | 11 (7-52) | 14 (7-49) | ns |
| Median days (range) of total antiviral therapy | 17 (6-69) | 17 (5-69) | ns |
| Median days (range) of total antiviral therapy: | |||
| in patients with grade 0-I acute GvHD | 12 (6-20) | 14 (7-66) | ns |
| in patients with grade II-IV acute GvHD | 20 (6-69) | 23 (5-69) | ns |
| P grade 0-I vs grade II-IV | (0.08) | (ns) | na |
No patients from either arm contracted HCMV disease.
na indicates not applicable; ns, not significant.